膀胱移行细胞癌组织中前胸腺素α的表达及其临床意义  

The clinical significance of Prothymosin-α protein expression in human bladder transitional cancer

作　　者：林哲[1] 邓玮明[2] 何娅娣[3] 李辽源[2] 

机构地区：[1]中山大学附属佛山医院佛山市第一人民医院泌尿外科,广东佛山528000 [2]中山大学附属第三医院泌尿外科 [3]中山大学附属第三医院体检中心

出　　处：《临床泌尿外科杂志》2012年第8期598-600,共3页Journal of Clinical Urology

基　　金：2008年广东省医学科研基金项目(编号B2008164);第42批中国博士后科学基金项目(编号20070420795);第一批中国博士后科学基金特别资助项目(编号200801264)

摘　　要：研究前胸腺素α(PTMA)在膀胱移行细胞癌组织中的表达情况,并分析其与膀胱癌临床病理特征的关系。方法:选择96例膀胱移行细胞癌标本,10例癌旁正常膀胱组织标本。采用免疫组化检测膀胱癌和癌旁正常组织中PTMA蛋白的表达。癌标本中非肌层浸润性癌51例,肌层浸润性癌45例;单发肿瘤57例,多发肿瘤39例;G122例、G231例、G343例;非肌层浸润性癌中未复发29例,复发22例。结果:随病理分级和临床分期增加,PTMA相对表达量逐渐增高。G1、G2、G3膀胱癌PTMA蛋白表达阳性率分别为13.6%、32.3%,62.8%,均差异有统计学意义(P<0.05)。正常膀胱组织中无PTMA蛋白表达。非肌层浸润性肿瘤和肌层浸润性肿瘤中PTMA蛋白表达阳性率为37.3%和77.8%,差异有统计学意义(P=0.0002)。随访12～60个月,非肌层浸润性膀胱癌中,复发组与未复发组中PTMA蛋白高表达阳性率为68.2%和31.0%,差异有统计学意义(P<0.001))。结论:检测膀胱移行细胞癌组织中PTMA有助于膀胱癌的诊断及评估判断,PTMA蛋白高表达与膀胱尿路上皮癌的恶性程度及预后相关。Objective ： To explore the expression of Prothymosin-α （PTMA） in bladder transitional cell carcino- ma and analyze its clinical significance and relationship with tumor recurrence. Methods.. The expressions of PTMA protein in 96 specimens of bladder cancer and 10 specimens of normal bladder tissues were detected by immunohis- tochemical staining and its clinical significance was analyzed. Results： PTMA protein expression rates were 13.6 %, 32.3 %, and 62.8 % in G1, G2, and G3 tumors, respectively（P〈0.05）. PTMA protein expression was high- er in muscle invasive bladder cancers than in non-muscle invasive bladder cancer （77.8% versus 37.3%, P = 0. 0002）. The expression of PTMA protein was higher in bladder cancer than that in the adjacent normal tissues. In patients with non-muscle invasive bladder cancer, PTMA protein expression was significantly higher in patients with recurrence than in those without recurrence （68.2% versus 31.0% ,P〈0. 001）. Conclusions：The determina- tion of PTMA protein expression is potentially valuable in diagnosis and prognostic evaluation for bladder transi- tional cell carcinoma.

关 键 词：膀胱移行细胞癌 前胸腺素α 复发 

分 类 号：R737.14[医药卫生—肿瘤]